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Recognition of pathogen-associated molecules in microbes by TLRs 
leads to activation of transcription factors such as NF-κB that pro-
mote increased transcription of proinflammatory cytokines and 
interferons1. All mammalian TLRs, with the exception of TLR3, use 
the adaptor MyD88 as the receptor-proximal signaling molecule 
to trigger downstream activation of NF-κB2. The association of 
MyD88 with TLRs facilitates recruitment of members of the IRAK 
 family of kinases that in turn activate the E3 ubiquitin ligase TRAF6 
(refs. 3–5). The formation of polyubiquitin chains by TRAF6 serves 
to bring TAK1 into close proximity with its substrates, including IκB 
kinases (IKKs). The TAK1-induced phosphorylation and activation of 
IKKα and IKKβ promotes IKK-induced phosphorylation of IκB pro-
teins6 that normally sequester NF-κB in an inactive form in the cyto-
plasm. Phosphorylated forms of IκB are subject to polyubiquitination 
and subsequently proteasome-dependent degradation, thus liberating 
NF-κB to translocate to the nucleus and transcriptionally upregulate 
the expression of a plethora of genes7. Most TLRs use this MyD88-
 dependent pathway to activate NF-κB, but TLR4 can additionally 
deploy another adaptor protein, TRIF, to trigger a MyD88-independent 
pathway that also activates NF-κB8. Among TLRs, TLR3 uses TRIF 
as its exclusive receptor-proximal adaptor protein. TRIF interacts 
with RIP1 kinase to trigger downstream IKK-mediated activation of 
NF-κB9,10. TRAF6 has been reported to associate with TRIF and 
mediate activation of NF-κB11–13, but other studies had concluded 
that TRAF6 is dispensable for TLR3 signaling14,15. Such discrepan-
cies in relation to the role of TRAF6 in TRIF signaling may be due to 
cell-specific roles for TRAF6 and/or functional redundancy of TRAF6 
with other members of the TRAF family11. In addition to activation 
of NF-κB, TRIF can also trigger activation of interferon-regulatory 
 factor (IRF) transcription factors. Thus, TRIF forms a complex with 
the kinases TBK1 and IKKi (also known as IKKε) and both kinases can 
catalyze phosphorylation and activation of IRF3 and IRF7, leading to 
their nuclear translocation and induction of type I interferons1,16. The 
latter are key antiviral molecules that block viral replication17,18.
It is clear from the above that ubiquitination is important in TLR 
signal transduction. Additionally, there is an emerging appreciation 
of the roles of the E3 ubiquitin ligase family of Pellino proteins in TLR 
signaling. The mammalian Pellino family consists of four members: 
Pellino1, Pellino2 and splice variants of Pellino3 termed Pellino3 long 
(Pellino3L; also known as Pellino3a) and Pellino3 short (Pellino3S; 
also known as Pellino3b)19,20. Each Pellino family member contains 
an N-terminal forkhead–associated (FHA) domain that recognizes 
phosphothreonine residues and mediates association with IRAKs21, 
and a C-terminal RING-like domain that confers E3 ubiquitin ligase 
activity and an ability to catalyze lysine 63 (Lys63)-linked polyubiq-
uitination of IRAKs22–24. Pellino proteins are subject to various forms 
of post-translational modification, including phosphorylation24–28, 
ubiquitination23–25 and sumoylation29 with phosphorylation being 
especially important for enhancing the E3 ligase activity. Pellino1 is 
regulated at the transcriptional level by TRIF signaling, which induces 
Pellino1 expression in an IRF3-dependent manner26. Although each 
of the Pellino proteins has most of the above features, there are unique 
functional differences. Pellino1 has been shown to act as a mediator 
in the NF-κB pathway30, whereas Pellino2 and Pellino3 have been 
associated with activation of MAPK pathways28,31–34. The generation 
of Pellino1-deficient mice had revealed a role for Pellino1 as the E3 
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Toll-like receptors (TLRs) sense pathogen-associated molecules and respond by inducing cytokines and type I interferon. Here 
we show that genetic ablation of the E3 ubiquitin ligase Pellino3 augmented the expression of type I interferon but not of 
proinflammatory cytokines in response to TLR3 activation. Pellino3-deficient mice had greater resistance against the pathogenic 
and lethal effects of encephalomyocarditis virus (EMCV). TLR3 signaling induced Pellino3, which in turn interacted with 
and ubiquitinated TRAF6. This modification suppressed the ability of TRAF6 to interact with and activate IRF7, resulting in 
downregulation of type I interferon expression. Our findings highlight a new physiological role for Pellino3 and define a new 
autoregulatory network for controlling type I interferon expression.
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ubiquitin ligase for RIP1 and a critical mediator of TRIF-dependent 
activation of NF-κB in TLR3 and TLR4 pathways35. Pellino1 has been 
shown to negatively regulate T cell activation and suppress autoim-
munity by promoting ubiquitination and proteolysis of the NF-κB 
subunit c-Rel in activated T cells36,37. To date the physiological roles 
of Pellino2 and Pellino3 remain to be defined.
We report the generation of Pellino3-deficient mice and describe 
a new physiological role for Pellino3 in TLR signaling. We show 
that Pellino3 is dispensable for TLR-induced expression of proin-
flammatory cytokines but has a negative regulatory role in TLR3- 
and viral-induced expression of type I interferon and related genes. 
Mechanistically, we show that TRIF signaling induces Pellino3 
expression, which in turn inhibits the ability of TRAF6 to activate 
IRF7. These findings reveal Pellino3 as an important player in a new 
autoregulatory system for controlling type I interferon expression.
RESULTS
Pellino3 regulates TLR3 induction of type I interferon 
We generated Pellino3-deficient mice with a floxed Peli3 allele 
(Supplementary Fig. 1a). We detected wild-type and recombined 
alleles by PCR analysis (Supplementary Fig. 1b). Semi-quantitative 
and real-time RT-PCR analysis of mRNA isolated from mouse embry-
onic fibroblasts (MEFs) demonstrated absence of Pellino3 mRNA 
expression in cells from Peli3−/− mice (Supplementary Fig. 1c,d). 
Initially we used bone marrow–derived macrophages (BMDMs) 
from wild-type and Peli3−/− mice to assess the effects of Pellino3 
deficiency on TLR signaling. The ability of various TLR ligands to 
induce proinflammatory cytokines, such as TNF and IL-6, was com-
parable in BMDMs from wild-type and Pellino3-deficient mice as 
determined by enzyme-linked immunosorbent assay (ELISA; Fig. 1a), 
indicating a nonessential role for Pellino3 in mediating TLR-induced 
expression of proinflammatory cytokines. Various TLR ligands were 
similarly effective in inducing TNF in MEFs isolated from wild-
type and Peli3−/− mice (Supplementary Fig. 2a). Given that TLRs 
are highly expressed in various dendritic cell (DC) populations, we 
characterized the effects of Pellino3 deficiency on IL-6 expression in 
response to TLR3, TLR4 and TLR9 signaling in myeloid DCs (mDCs) 
and plasmacytoid DCs (pDCs; Supplementary Fig. 2b,c). Absence 
of Pellino3 had no effect on the TLR-mediated induction of IL-6 in 
these DC populations.
We next examined a potential role of Pellino3 in regulating the 
expression of type I interferons and interferon-stimulated genes, such 
as the chemokine CXCL10. We stimulated BMDMs with ligands for 
TLR3, TLR4, TLR7 and TLR9 because these are the predominant 
TLR family members that induce type I interferons, and measured 
the induction of interferon beta (IFN-β). Each of the ligands induced 
IFN-β in wild-type BMDMs, but the TLR3 agonist polyriboinosinic:
polyribocytidylic acid (poly(I:C)) was unique in that its efficacy in 
inducing IFN-β was augmented in Pellino3-deficient BMDMs com-
pared with wild-type BMDMs (Fig. 1b). Peli3−/− cells also exhibited 
selective enhancement of poly(I:C)-induced expression of CXCL10 
(Fig. 1c). Poly(I:C) similarly induced higher IFN-α expression in 
Peli3−/− BMDMs relative to their wild-type counterparts (Fig. 1d). 
The type I interferon produced in these cells was bioactive, as shown in 
a type I interferon reporter cell line (Fig. 1e). We also measured type 
I interferon and CXCL10 induction in MEFs, mDCs and pDCs stimu-
lated with various TLR ligands (Supplementary Fig. 2). We observed 
enhanced induction of type I interferon and CXCL10 by poly(I:C) 
in Pellino3-deficient MEFs and mDCs. This effect was mediated 
by increased gene transcription because poly(I:C) induced greater 
amounts of Ifnb1 mRNA in Pellino3-deficient BMDMs relative to 
wild-type cells, whereas poly(I:C)-mediated induction of Tnf mRNA 
was independent of Pellino3 deficiency (Fig. 1f). The regulatory 
effects of Pellino3 on type I interferon expression seemed to be 
restricted to TLR3 because Pellino3 deficiency did not affect LPS-
mediated induction of Ifnb1 or Tnf mRNA in BMDMs (Fig. 1g).
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Figure 1 Pellino3 deficiency results in enhanced TLR3-induced expression of IFN-β and related genes. (a) ELISA of TNF and IL-6 expression in 
medium from BMDMs isolated from wild-type (WT) and Pellino3-deficient (Peli3−/−) mice and treated with 10 ng/ml Pam2CSK, 10 ng/ml Pam3CSK,  
1 µg/ml zymosan, 5 µg/ml poly(I:C), 10 ng/ml lipopolysaccharide (LPS), 1 µg/ml flagellin, 1 µg/ml CLO97 and 2 µg/ml CpG for 24 h. UT, untreated. 
(b,c) ELISA of IFN-β (b) and CXCL10 (c) in medium from WT and Peli3−/− BMDMs stimulated with 5 µg/ml poly(I:C), 10 ng/ml LPS, 1 µg/ml CLO97 and 
5 µg/ml CpG for 24 h. (d,e) Expression of IFN-α assayed by ELISA (d) and bioactive type 1 interferon assayed by blue sensor cells (e) in WT and Peli3−/− 
BMDMs stimulated with 5 µg/ml poly(I:C) for 24 h. (f,g) Quantitative PCR of mRNA expression for Ifnb1 and Tnf in WT and Peli3−/− BMDMs that were 
untreated or stimulated with 5 µg/ml poly(I:C) (f) or 10 ng/ml LPS (g) for 6 h. ND, not detected. (h) Quantitative PCR of IFN-β, RANTES and TNF mRNA 
expression in PECs isolated from WT and Peli3−/− mice 48 h after intraperitoneal injection with 1 mg/kg poly(I:C). Data are representative of three 
experiments (error bars, s.e.m.; n =3). *P < 0.05, **P < 0.01 and ***P < 0.001 (paired Student’s t-test).
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To confirm the regulatory effects of Pellino3 in poly(I:C) signaling 
in vivo, we injected wild-type and Pellino3-deficient mice intraperi-
toneally with poly(I:C), isolated peritoneal exudate cells (PECs) and 
assayed them for expression of genes encoding IFN-β, RANTES and 
TNF (Ifnb1, Ccl5 and Tnf, respectively). The chemokine RANTES was 
included in this analysis because, similar to type I interferon, its expres-
sion is regulated by IRFs. In vivo administration of poly(I:C) induced 
expression of Ifnb1 and Ccl5 in wild-type mice, and this was enhanced 
in Pellino3-deficient mice (Fig. 1h). In contrast, poly(I:C)-mediated 
induction of Tnf was similar in wild-type and Peli3−/− mice, indicating 
that Pellino3 selectively regulates expression of type I interferons and 
related genes without affecting expression of proinflammatory genes.
Given that poly(I:C) can stimulate both TLR3 and the cytosolic 
receptor MDA-5 (ref. 38), we investigated which of the two pathways 
is potentially modulated by Pellino3 in this experimental system. 
We observed loss of induction of Ifnb1, Ccl5 and Tnf mRNAs, which 
encode IFN-β, RANTES and TNF, respectively, in response to poly 
(I:C) in TRIF-deficient BMDMs but not in BMDMs deficient in the 
signaling adaptor MAVS (Supplementary Fig. 3a). Given the role of 
TRIF in TLR3 signaling and MAVS in MDA-5 signaling, these results 
provide evidence that TLR3 is the primary sensing receptor for poly(I:C) 
in BMDMs. In addition, we applied poly(I:C) to cells directly, which 
favors stimulation of TLR3, whereas MDA-5–mediated responses 
to poly(I:C) require transfection of cells for delivery of the synthetic 
dsRNA to the cytosol. To confirm that Pellino3 targets TLR3 in our 
model, we tested the effect of direct application or liposome-mediated 
delivery of poly(I:C) to wild-type and Pellino3-deficient BMDMs on 
IFN-β expression. Both delivery methods induced IFN-β in wild-type 
BMDMs. IFN-β induction was enhanced in Pellino3-deficient cells in 
response to direct application of poly(I:C) but not in response to trans-
fection-mediated delivery (Supplementary Fig. 3b). These findings 
suggest that Pellino3 selectively targets the TLR3 pathway.
We next addressed the regulatory effects of Pellino3 on TLR3-
induced expression of type I interferon and related genes in human 
cells. We established U373 cell lines transduced with lentivirus to 
stably express PELI3-specific short hairpin RNA (shRNA) or a cont-
rol shRNA. We confirmed knockdown of Pellino3 expression by RT-
PCR (Supplementary Fig. 4a). Expression of IFNB1, IFNA1, CCL5 
and CXCL10 mRNA, in response to poly(I:C) stimulation for various 
times, was greatly enhanced under conditions of Pellino3 knockdown 
(Supplementary Fig. 4b–e). We also observed enhanced expression at 
the protein level (Supplementary Fig. 4f,g). Poly(I:C)-induced expres-
sion of IL6 mRNA or protein were not affected in Pellino3 knockdown 
U373 cells (Supplementary Fig. 4h,i). Together, these results indicate 
a selective role for Pellino3 as a negative regulator of TLR3-induced 
expression of type I interferon but not of proinflammatory genes.
Enhanced protection from EMCV infection in Peli3−/− mice 
Given that poly(I:C) is a synthetic analog of viral dsRNA, we inves-
tigated the role of Pellino3 in regulating the host response to EMCV, 
which generates dsRNA as part of its life cycle and for which TLR3 
signaling has been shown to be important for a protective response39. 
EMCV induced IFN-β, IFN-α, CXCL10 and TNF in wild-type 
BMDMs. Whereas expression of type I interferon and CXCL10 was 
additionally enhanced in Peli3−/− cells, EMCV-induced TNF was 
not affected by Pellino3 deficiency (Fig. 2a). We obtained similar 
results in Pellino3-deficient MEFs (Fig. 2b). The enhanced produc-
tion of type I interferons was bioactive (Fig. 2c). Pellino3-deficient 
MEFs showed enhanced induction of the mRNAs encoding IFN-β, 
IFN-α and CXCL10 in response to EMCV challenge relative to wild-
type cells (Fig. 2d). Loss of Pellino3 had no effect on the Tnf mRNA 
induced by EMCV, suggesting Pellino3 specifically regulates type I 
interferon gene expression in response to EMCV.
We next investigated the physiological and pathological relevance 
of these regulatory effects of Pellino3 in the context of EMCV infec-
tion with two lethal viral doses in wild-type and Peli3−/− mice. 
The higher infection dose of 250 plaque-forming units (PFU) per 
mouse had a lethal effect in all wild-type mice 7 d after infection 
(Fig. 3a), whereas 60% of Pellino3-deficient mice survived and 
remained healthy for the duration of the infection study. A lower 
dose of EMCV (50 PFU per mouse) caused 50% lethality in wild-
type mice 10 d after infection, whereas all Pellino3-deficient mice 
survived (Fig. 3a). An increased heart/body weight ratio, characteri-
stic of EMCV infections, was clearly evident in wild-type mice but 
not in Pellino3-deficient mice at low doses of infection (Fig. 3b). 
Examination of heart tissue from EMCV-infected wild-type mice 
by microscopy revealed histopathological changes with random 
multifocal mononuclear interstitial infiltrates as well as myofiber 
nuclear karyolysis and myofiber cell loss accompanied by mild 
edema (Fig. 3c). We did not observe these changes in the heart tis-
sue from EMCV-infected Peli3−/− mice. Enhanced protection from 
the pathological and lethal effects of EMCV infection in Pellino3-
deficient mice was associated with a lower viral load in the hearts, as 
measured by expression of the replicase gene from EMCV (Fig. 3d). 
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Figure 2 Pellino3-deficient cells exhibit an enhanced type 1 interferon 
response to EMCV infection. (a,b) ELISA of IFN-β, IFN-α, CXCL10 
and TNF expression in medium from BMDMs (a) or MEFs (b) isolated 
from wild-type (WT) and Peli3−/− mice and infected with EMCV (250 
PFU)) for the indicated durations. (c,d) Expression of bioactive type 
1 interferon assayed in blue sensor cells (c) and quantitative PCR of 
Ifnb1, Cxcl10, Ifna and Tnf mRNA expression (d) in WT and Peli3−/− 
MEFs infected with EMCV (250 PFU) for the indicated durations.  
Error bars, s.e.m. (n = 3 experiments). NS, not significant,*P < 0.05, 
**P < 0.01 and ***P < 0.001 (paired Student’s t-test). 
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This was consistent with enhanced IFN-β expression in the hearts 
from EMCV-infected Peli3−/− mice (Fig. 3e), which presumably 
facilitated more efficient clearance of the virus. Expression of TNF 
in the heart of EMCV-infected Peli3−/− mice was lower than that in 
infected wild-type mice (Fig. 3f), correlating with the lower grade 
of inflammation suggested by the histochemical analysis (Fig. 3c). 
Thus, Pellino3 has an important regulatory function in controlling 
type I interferon expression in response to viral challenge.
Pellino3 selectively regulates activation of IRF7 
Because the type I interferon and related genes that are inhibited by 
Pellino3 are strongly regulated by NF-κB and IRFs, we compared 
these pathways in response to poly(I:C) in wild-type and Pellino3-
deficient cells. The absence of Pellino3 did not affect the capacity 
of poly(I:C) to induce phosphorylation of IKKs or of their substrate 
IκBα, both of which are activation indices of the canonical NF-κB 
pathway (Fig. 4a). To investigate the activation of IRFs, we assessed 
the binding of nuclear extracts to an oligonucleotide containing 
the IRF recognition motif from the positive regulatory domains 
I/III (PRD I/III) of the enhancer region of the Ifnb1 gene. Poly(I:C) 
induced a modest and time-dependent increase in the binding of 
nuclear extract proteins from wild-type cells to the PRD I/III motif, 
whereas binding was enhanced in extracts from Pellino3-deficient 
cells (Fig. 4b), suggestive of a role for Pellino3 in targeting the IRF 
arm of the TLR3 pathway. However, loss of Pellino3 did not affect 
the ability of poly(I:C) to promote phosphorylation of IRF3 or its 
upstream kinase TBK1 (Fig. 4c). Given that IRF7 can also bind to 
the PRD I/III domain, we probed the regulatory effect of Pellino3 
on the phosphorylation of IRF7, which is required for its activa-
tion. Because commercially available phosphospecific IRF7 anti-
bodies are only sufficiently sensitive to detect overexpressed IRF7, 
we characterized the poly(I:C)-induced phosphorylation of IRF7 
expressed in HEK293 cells, stably expressing TLR3 and transfected 
with shRNA targeting PELI3. In this system, poly(I:C) promoted 
time-dependent phosphorylation of IRF7 in cells transfected with a 
control shRNA, and this was enhanced in Pellino3-knockdown cells 
(Fig. 4d). We next probed the regulatory effect of Pellino3 on the 
phosphorylation of endogenous IRF7. Given the lack of sensitivity 
of the phospho-IRF7 antibody, we immunoblotted for serine phos-
phorylation of IRF7 immunoprecipitated from mDCs that had been 
stimulated with poly(I:C). The amount of serine-phosphorylated 
IRF7 was higher in Pellino3-deficient mDCs relative to that in 
wild-type mDCs (Fig. 4e).
Because phosphorylation of IRF7 is a prerequisite for its nuclear 
translocation, we next assessed the effects of Pellino3 deficiency on 
the nuclear localization of IRF7. We isolated nuclear fractions from 
wild-type and Pellino3-deficient BMDMs that had been stimulated 
with poly(I:C) for various durations. Time-dependent poly(I:C)-
induced nuclear localization of IRF7 was stronger in Peli3−/− than 
in wild-type BMDMs (Fig. 4f). Whereas poly(I:C) also caused 
increased nuclear localization of IRF3, this was not affected by 
the absence of Pellino3. We used confocal microscopy to comple-
ment these observations on the subcellular localization of IRF7. 
In unstimulated MEFs from wild-type mice, IRF7 localized to the 
cytoplasm, and stimulation with poly(I:C) promoted some nuclear 
accumulation of IRF7 (Fig. 4g). However, the effect of poly(I:C) in 
Pellino3-deficient MEFs was more notable, with all detectable IRF7 
translocating to the nucleus after poly(I:C) stimulation. Finally, we 
assessed whether the enhanced poly(I:C)-induced nuclear locali-
zation of IRF7 in Pellino3-deficient cells translated into increased 
binding of IRF7 to responsive promoters. We stimulated wild-
type and Pellino3-deficient BMDMs with poly(I:C) and assayed 
the in vivo binding of IRF7 to the Ifnb1 promoter by chromatin 
 immunoprecipitation. Poly(I:C)-induced binding of IRF7 to the Ifnb 
promoter was increased in Pellino3-deficient cells compared to that 
in wild-type BMDMs (Fig. 4h).
All of the above data strongly indicate that Pellino3 negatively reg-
ulates activation of IRF7 but not of IRF3. We directly addressed this 
by assessing the effects of overexpressed Pellino3 on the induction 
of a cotransfected IRF3-regulated or IRF7-regulated reporter gene. 
Using this system, both spliced forms of Pellino3 inhibited poly(I:C)- 
induced activation of IRF7 but not of IRF3 (Supplementary 
Fig. 5a,b), consistent with Pellino3 targeting the IRF7 pathway. 
We also characterized the regulatory effects of the spliced forms 
of Pellino3 on naturally occurring IRF7-responsive promoters. 
Both spliced forms inhibited poly(I:C)-induced activation of the 
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IFNA4 and IFNB promoters (Supplementary Fig. 5c,d). Furthermore, 
given that IRF7 binds to the PRDI/III domains of the IFNB promoter, 
we confirmed that Pellino3 targets this region of the IFNB promoter 
(Supplementary Fig. 5e). These data suggest that Pellino3 regulates 
the nuclear translocation and activation of IRF7.
Pellino3 regulates TRAF6-dependent ubiquitination of IRF7 
We next probed the mechanism by which Pellino3 can target the 
IRF7 pathway. Because loss of Pellino3 did not affect poly(I:C)-
induced phosphorylation of TBK1, a known activator of IRF7, we 
investigated the effects of Pellino3 deficiency on the ubiquitination 
status of IRF7. Previous studies have demonstrated that ubiquitina-
tion of IRF7 is a prerequisite for IKKi-mediated phosphorylation 
and activation of IRF7 (refs. 40,41). Poly(I:C) promoted a modest 
increase in the ubiquitination of IRF7 in MEFs from wild-type 
mice. This was considerably enhanced in MEFs from Peli3−/− mice 
(Fig. 5a). Given that TRAF6 has been shown to interact with and 
ubiquitinate IRF7 (refs. 40,41), we next probed the effects of Pellino3 
on the TRAF6-IRF7 interaction. Poly(I:C) promoted the interaction 
of TRAF6 with IRF7 in wild-type MEFs, and this was augmented 
in Peli3−/− MEFs, as shown by increased coimmunoprecipitation of 
TRAF6 and IRF7 (Fig. 5b). Poly(I:C) did not induce IFN-β in MEFs 
from TRAF6-deficient mice (Fig. 5c), demonstrating a functional 
role for TRAF6 in poly(I:C)-induced expression of type I interferon. 
This deficiency in TLR3 signaling was rescued by reconstitution of 
Traf6−/− MEFs with wild-type TRAF6 but not with a point mutant 
form of TRAF6 (C70A) that obliterates its E3 ubiquitin ligase activity 
(Fig. 5d). These results are consistent with a model in which Pellino3 
targets TRAF6-induced ubiquitination of IRF7 and IFN-β expression 
downstream of TLR3.
Pellino3 mediates ubiquitination of TRAF6
We next investigated the regulatory process by which TLR3 deploys 
Pellino3 to negatively regulate TRAF6-mediated activation of IRF7. 
Poly(I:C) induced expression of Peli3 mRNA in wild-type BMDMs 
(Fig. 6a) but not in BMDMs lacking TRIF, TBK1 or IKKi. In addi-
tion, poly(I:C) promoted the interaction of Pellino3 with TRAF6 in 
a time-dependent manner, as evidenced by coimmunoprecipitation 
of the two proteins (Fig. 6b). We probed the functional consequence 
of this interaction by measuring the ubiquitination of TRAF6 in 
wild-type and Pellino3-deficient cells. Because Pellino3 is an E3 
ubiquitin ligase, we especially investigated the ubiquitination of 
TRAF6. Stimulation with poly(I:C) caused ubiquitination of TRAF6 
in wild-type MEFs but not in MEFs from Peli3−/− mice (Fig. 6c), 
indicating an important role for Pellino3 in the ubiquitination of 
TRAF6 downstream of TLR3. This was also the case in human cells, 
as HEK293 cells stably expressing TLR3 and transfected with PELI3-
specific shRNA did not exhibit increased ubiquitination of TRAF6 
in response to poly(I:C), whereas cells transfected with control 
shRNAs strongly responded to poly(I:C) (Supplementary Fig. 6a). 
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The responsiveness of Peli3−/− MEFs to poly(I:C)-induced ubiquiti-
nation of TRAF6 was restored by retrovirally mediated expression 
of mouse Pellino3 (Supplementary Fig. 6b). The E3 ligase activity 
of Pellino3 was directly required for the ubiquitination of TRAF6 
because a mutant form of Pellino3 that lacks a functional RING 
domain did not reconstitute the poly(I:C)-induced ubiquitination 
of TRAF6 in Peli3−/− MEFs (Fig. 6d).
We next evaluated the functional link between the ability of 
Pellino3 to mediate poly(I:C)-induced ubiquitination of TRAF6 
and the regulatory effects of Pellino3 on IFN-β expression. 
Reintroduction of mouse Pellino3 into Peli3−/− MEFs blunted the 
ability of poly(I:C) to induce Ifnb1 mRNA and IFN-β protein, 
whereas the mutated form of Pellino3 with a nonfunctional RING 
domain did not exert this inhibitory influence (Fig. 6e). This also 
applies to human cells because exogenous expression of Pellino3 
in HEK293 TLR3 cells expressing PELI3-specific shRNA inhibited 
poly(I:C)-induced expression of IFN-β, whereas the RING-mutated 
form of Pellino3 was ineffective (Supplementary Fig. 6c). We next 
explored whether ubiquitination of TRAF6 affects its capacity to 
ubiquitinate IRF7. As expected, the coexpression of TRAF6 and 
IRF7 led to strong ubiquitination of IRF7, and this was lost with a 
point mutation (C70A) of TRAF6 that interferes with the E3 ligase 
activity of TRAF6 (Fig. 6f). However, mutation of the primary ubiq-
uitination site in TRAF6 (Lys124) led to slightly higher levels of 
ubiquitinated IRF7, consistent with the idea that ubiquitination of 
TRAF6 has an inhibitory effect on its E3 ubiquitin ligase activity. 
Furthermore, the TRAF6 mutant lacking the ubiquitination site 
was more effective than its wild-type counterpart in reconstituting 
poly(I:C)-induced expression of IFN-β in TRAF6-knockdown cells 
(Fig. 6g). These data are consistent with a model where poly(I:C) 
induces Pellino3 expression and promotes its interaction with and 
Figure 5 Loss of Pellino3 enhances binding of TRAF6 to IRF7 and 
ubiquitination of IRF7. (a,b) Immunoblot (IB) analysis of IRF7 and 
ubiquitin (a) or TRAF6 (b) in lysates and immunoprecipitated (IP) IRF7 
samples from wild-type (WT) and Peli3−/− MEFs stimulated with 25 µg/ml 
poly(I:C) for indicated durations. β-actin was used as a loading control. 
(c) Quantitative PCR of mRNA expression for IFN-β in WT, Peli3−/− and 
Traf6−/− MEFs stimulated or untreated (UT) with 25 µg/ml poly(I:C) for  
6 h. (d) Quantitative PCR of mRNA expression for IFN-β in Traf6−/− MEFs 
transfected with an empty vector (EV) construct or expression plasmids 
encoding WT TRAF6 or TRAF6 (C70A) (3 µg) and stimulated with 25 µg/ml 
poly(I:C) for 6 h or untreated (UT). Expression of TRAF6 constructs in 
Traf6−/− MEFs was determined by immunoblotting. Immunoprecipitation 
experiments (a,b) are representative of three experiments. Error bars 
(c,d), s.e.m. (n = 3 experiments). *P < 0.05, ***P < 0.001 and NS, not 
significant (paired Student’s t-test). 
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ubiquitination of TRAF6, thus negatively influencing the ability of 
the latter to ubiquitinate IRF7 and induce IFN-β expression.
DISCUSSION
Using Pellino3-deficient mice, in this study we characterized the 
physiological role of Pellino3 in innate immunity. Peli3−/− mice were 
viable and developed normally. Our data indicate that Pellino3 does 
not act as a mediator of proinflammatory cytokine expression in 
response to TLRs but has a key regulatory role in controlling TRIF-
dependent type I interferon expression in the TLR3 pathway. We pro-
pose that TLR3 specifically uses Pellino3 as part of an autoregulatory 
signaling network in which stimulation of TLR3 by viruses or defined 
ligands, such as dsRNA, leads to upregulation of Pellino3, facilitat-
ing its interaction with TRAF6 and ubiquitination of the latter. We 
propose that this modification of TRAF6 serves to terminate its abi-
lity to ubiquitinate IRF7, thus shutting down a key driver of type I 
interferon expression.
In addition to delineating a new regulatory network that con-
trols type I interferon expression, the findings also highlight a new 
 function for Pellino proteins. Whereas overexpression and knock-
down approaches have previously implicated Pellino proteins as 
regulators of the NF-κB and MAP kinase pathways, studies in a 
physiological setting have been restricted to Pellino1 (refs. 35, 36). 
Using Pellino1-deficient mice, Pellino1 has been shown to regulate the 
NF-κB pathway and act as a key mediator of TRIF-induced expression 
of proinflammatory cytokines in the TLR3 and TLR4 pathways. Our 
present studies show that Pellino3 regulates TRIF-dependent signal-
ing in a manner that is very different from that of Pellino1, in that 
Pellino3 regulates TRIF-induced expression of IFN-β. This empha-
sizes divergent functions for different members of the Pellino family 
and highlights specific roles for Pellino proteins in these pathways.
We used EMCV as a naturally occurring agent that triggers anti-
viral immunity via TLR3. TLR3 signaling is essential for mediating 
cytokine expression, viral clearance and reducing lethality in response 
to EMCV infection39. Our findings indicate that absence of Pellino3 
leads to enhanced viral clearance, diminished pathology and greater 
survival in mice, and this is consistent with greatly augmented TLR3-
induced expression of type I interferons in response to EMCV infec-
tion when Pellino3 is absent. This reaffirms a critical role for Pellino3 
in tempering type I interferon expression in response to TLR3 stimu-
lation. However, our findings cannot exclude a role for Pellino3 in 
similarly regulating the signaling of the viral sensing retinoic acid-
inducible gene (RIG-I)-like receptors, as Mda-5 has also been reported 
to detect poly(I:C) and act as a sensor of EMCV infection and as a 
mediator of EMCV-driven type I interferon expression38. However, 
responses to poly(I:C) mediated by Mda-5 require cell transfection 
to facilitate delivery of the synthetic dsRNA to the cytosol-resident 
Mda-5. Under conditions of transfection-mediated delivery, we 
showed that loss of Pellino3 was without effect, strongly suggesting 
that Pellino3 targets the TLR3 pathway and not the Mda-5 pathway. 
Furthermore, using our delivery protocol, we observed loss of cytokine 
induction in response to poly(I:C) in TRIF-deficient BMDMs but not 
in MAVS-deficient BMDMs, reaffirming that Pellino3 is targeting 
the TLR3 pathway.
In our model, Pellino3 negatively regulates ubiquitination, nuclear 
translocation and activation of IRF7, and thus inhibits a major driver 
behind type I interferon expression. In searching for the mechanism 
by which Pellino3 could exert such effects on IRF7 activation we 
looked beyond its immediate upstream kinases, TBK1 and IKKi, given 
that loss of Pellino3 did not affect poly(I:C)-induced phosphorylation 
of TBK1. A previous study has shown that Epstein-Barr virus LMP1 
uses TRAF6 to ubiquitinate IRF7 on its last three lysine residues, with 
such ubiquitination being a prerequisite for IKKi-mediated phosphory-
lation and activation of IRF7 (ref. 41). TRAF6 also has been shown to 
fulfill a critically important role in the ubiquitination and activation 
of IRF7 by TLR7 and TLR9 in pDCs40. TRAF6 has a role in the activa-
tion of the IFN-β promoter by poly(I:C) and EMCV, with the replica-
tion of EMCV being considerably enhanced in the absence of TRAF6 
(ref. 42). These reports closely mirrored our findings in Pellino3-
 deficient mice and promote TRAF6 as the lead target for Pellino3.
We found that TLR3 signaling promoted the interaction of Pellino3 
with TRAF6, leading to strong ubiquitination of TRAF6, which 
depended on the functional RING-like domain in Pellino3. These 
observations strongly suggest that Pellino3 acts as the immediate E3 
ubiquitin ligase for TRAF6. However, this does not exclude the possi-
bility that Pellino3 associates with TRAF6 and stimulates the auto-
ubiquitination of TRAF6. In an in vitro ubiquitination assay, we did 
not observe direct ubiquitination of TRAF6 by recombinant Pellino3. 
This may be due to recombinant Pellino3 lacking some prerequisite 
modification or ancillary protein to manifest its E3 ligase activity 
to TRAF6. Indeed the E3 ligase catalytic activity of Pellino proteins 
is strongly enhanced by phosphorylation24–28, and in the context 
of TLR3 signaling it is especially interesting to note that Pellino1 
is induced and activated by TBK1 and IKKi26. We showed here that 
the expression of Pellino3 similarly depends on TBK1-IKKi. Thus it 
is plausible to extrapolate a model where TLR3 signaling uses TBK1 
and IKKi, in an analogous manner to Pellino1, to phosphorylate and 
activate Pellino3, thus leading to ubiquitination of TRAF6.
We also propose that Pellino3-mediated ubiquitination of TRAF6 
negatively influences the ability of TRAF6 to ubiquitinate IRF7. 
Although the ubiquitination of TRAF6 has been originally proposed 
to serve to bring TAK1 and IKK complexes into close proximity, thus 
allowing for IKK activation and downstream activation of NF-κB43, 
this model has been questioned recently. Thus, a mutant form of 
TRAF6 that is refractory to ubiquitination can still trigger activation of 
NF-κB44, and TRAF6 can generate unanchored polyubiquitin chains to 
trigger downstream activation of NF-κB45. We now propose a new role 
for ubiquitination of TRAF6 in that it suppresses the ubiquitination of 
IRF7 by decreasing the interaction of TRAF6 with IRF7. It is intriguing 
that Pellino3 should counterregulate interferon expression by targeting 
the TRAF6-IRF7 interaction, as the Thogoto virus uses its ML protein as 
a virulence factor to inhibit the expression of type I interferons by also 
blocking the interaction of TRAF6 with IRF7 (ref. 46). This highlights a 
critical involvement for TRAF6-mediated ubiquitination of IRF7 in the 
induction of type I interferons. Given such an important role, it is not 
surprising that a physiological regulatory system modulates this part 
of the pathway to control type I interferon expression, whereas viruses 
target this pathway to subvert antiviral innate immunity.
Pellino proteins are very highly conserved throughout evolution, and 
so the notion of a Pellino gene being evolutionarily retained to counter 
a key antiviral strategy of producing type I interferon appears counter-
intuitive. However, the expression of type I interferons must be tightly 
controlled because excessive production can contribute to autoimmune 
inflammatory diseases47. It will be interesting to explore whether natu-
rally occurring defective forms or expression of Pellino3 may provide a 
genetic basis to some cases of interferon-driven inflammatory disease. 
Such studies in conjunction with the present findings will help under-
stand the physiological and pathological roles of the Pellino family.
METHODS
Methods and any associated references are available in the online 
version of the paper.
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ONLINE METHODS
Plasmids and reagents. Mouse Pellino3 was cloned from embryo brain and 
into the retroviral MSCV2.2-IRES-GFP vector. Human TRAF6 C70A and 
K124R mutants and Traf6−/− MEFs were from A. Bowie (Trinity College 
Dublin). Immortalized wild-type, Ticam1−/−, Tbk1−/− and Ikbke−/− BMDMs 
were from K. Fitzgerald (University of Massachusetts Medical School). FLT3 
ligand was from C. Jefferies (Royal College of Surgeons Ireland). Anti-TRAF6 
(sc-7221), anti-ubiquitin (P4D1), anti-IRF3 (sc-9082) and anti-IRF7 (F-1) 
antibodies for coimmunoprecipitation were from Santa Cruz Biotechnology. 
The anti-IRF7 antibody (ab109255) for immunoblotting was from Abcam. 
Anti-phospho IκBα (9246), anti-phospho IKK (2694), anti-IKK (2684), 
anti-phospho TBK1 (D52C2), anti-TBK1 (3013), anti-phospho IRF3 (4D4G), 
anti-phospho IRF7 (5184) and anti-Myc (9B11) antibodies were from Cell 
Signaling Technology. The anti–phospho-serine antibody (AB1603) was from 
Millipore. The anti–β-actin antibody (AC-15) was from Sigma. The custom-
ized anti-human Pellino3 antibody was from GenScript. LPS was from Enzo 
Life Sciences and other TLR ligands were from Invivogen.
Mice. Peli3−/− mice were generated by Taconic Artemis using proprietary tech-
nology (Supplementary Fig. 1a). To generate constitutive Peli3−/− mice, mice 
that were heterozygous for the targeted allele were bred with mice containing 
Cre recombinase regulated by the Rosa26 locus (C57BL/6 Gt(ROSA)26Sortm16
(Cre)Arte). This results in the deletion of exon 3 and loss of function of the Peli3 
gene by generating a frame shift in all downstream exons. The Cre transgene 
was removed by breeding the resulting Peli3+/− mice with C57BL/6 mice dur-
ing colony expansion. Mice were genotyped by PCR analysis of DNA isolated 
from ear punches using primers ‘a’, CCCAACATAGGTGTTTCCTCTCC; ‘b’, 
GTGCATACACATTCATGCAAGC; ‘c’, GACACGTGTGGAGATAATGAGG; 
and ‘d’, ACCCAGGCACAAGTCAAGC. All animal experiments were per-
formed in accordance with the regulations and guidelines of the Irish 
Department of Health and protocols approved by the Research Ethics com-
mittee of National University of Ireland Maynooth.
EMCV infection. We injected 50 PFU or 250 PFU of EMCV intraperitoneally 
into 6-week-old wild-type or Peli3−/− mice. The day of virus inoculation was 
defined as day 0. Mice that became moribund were considered to have reached 
the end point of the experiment and were killed. Mice were killed 12 d or 14 d 
after infection, and ratio of heart weight to body weight was measured. Hearts 
were then fixed, sectioned at 5 µm and stained with hematoxylin and eosin. 
The pathologist (J.J.C.) was blinded to the genetic and infectious status of the 
mice. For cytokine and EMCV replicase analysis, mice were inoculated with 
50 PFU) EMCV and allowed recover for 4 d. Mice were killed and total RNA 
was extracted from tissue using TRI reagent (Sigma).
Cell culture. Peli3+/− mice were bred to generate wild-type and Peli3−/− 
embryos and MEFs. Bone marrow cells were maintained in macrophage-colony 
stimulating factor (M-CSF; 20 ng/ml) for 5–7 d, or granulocyte macrophage-
colony stimulating factor (GM-CSF; 10 ng/ml) or Fms-related tyrosine kinase 
3 ligand (FLT3L; 10 ng/ml) for 8–10 d to generate BMDMs, mDC or pDC cells, 
respectively. pDCs were enriched using a pDC isolation kit (Miltenyi Biotec). 
Purity of mDCs (~90% CD11c+ CD11b+ CD45R/B220−) and pDCs (~90% 
CD11c+ CD11b− CD45R/B220+) was assayed by flow cytometry using anti-
CD11c (N418), anti-CD11b (M1/70) and anti-CD45R/B220 (RA3-6B2) on live 
cells as determined by 7-AAD Viability Staining Solution (eBioscience).
Generation of peritoneal exudate cells (PECs). Age-matched and weight-
matched wild-type and Peli3−/− mice were injected intraperitoneally with 
1 mg/kg poly(I:C) for 48 h. PECs were isolated and relative expression of 
mRNAs encoding IFN-β, RANTES and TNF was determined by quantitative 
real-time RT-PCR.
ELISA and type I interferon bioassay. Mouse cells were seeded (5 × 105 
cells/ml; 200 µl) in 96-well plates and stimulated as indicated. Conditioned 
medium was measured for levels of TNF, IL-6 (DuoSet kits; R&D Systems), 
CXCL10 (ELISA development kit; Peprotech) and IFN-α (mouse IFN α 
Platinum ELISA; eBioscience) and mouse type I interferon by blue sensor cells 
(Invitrogen) according to manufacturer’s instructions. IFN-β protein levels 
were assayed by an in-house sandwich ELISA system. Conditioned superna-
tants from U373 shRNA stable cell lines were assayed for RANTES, CXCL10 
and IL-6 (DuoSet kits; R&D Systems).
Elecrophoretic mobility shift assay. MEFs were grown in 6-well plates for 
24 h. Cells were then stimulated with 25 µg/ml poly(I:C). Nuclear extracts were 
generated as previously described48 and incubated with an oligonucleotide 
containing the IFN-β PRD I/III-binding site 5′-GTAAATGACATAGGAAAA
CTGAAAGGGAGAAGTGAAAGTGG-3′ and labeled with IRDye 700 accord-
ing to the manufacturer’s instructions.
Immunoprecipitation studies. Primary MEFs or mDCs were seeded in 
cell-culture 90-mm dishes (5 × 105 cells/ml or 1 × 106 cells/ml, respectively) 
and stimulated with poly(I:C) for designated times. Cells were washed in 
1 ml of ice-cold PBS and lysed in 200 µl of radioimmunoprecipitation (RIPA) 
buffer: 50 mM Tris, 150 mM NaCl, 0.1% SDS (w/v), 0.5% sodium deoxycholate 
(w/v), 1% Triton X-100 (v/v) containing 1 mM Na3VO4, 1 mM dithiothreitol, 
1 mM phenylmethylsulfonyl fluoride and complete protease inhibitor mixture 
(Roche). Cell lysates were treated with 1% SDS and incubated at 95 °C for 
5 min to dissociate protein-protein interactions. Samples were then diluted 
tenfold with lysis buffer before immunoprecipitation and immunoblotting 
using indicated antibodies.
Coimmunoprecipitation studies. MEFs or U373 cells were seeded in 90-mm 
dishes (5 × 105 cells/ml) and stimulated with poly(I:C) for indicated durations. 
Cells were washed in 1 ml ice-cold PBS and lysed in 250 µl of lysis buffer 
(50 mM Hepes pH 7.5, 1 mM EDTA, 10% glycerol (v/v), 0.05% CHAPS (w/v), 
0.5% Triton X-100 (v/v), 250 mM NaCl containing 1 mM Na3VO4, 1 mM 
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and complete protease 
inhibitor mixture). Lysates were processed as described above for immuno-
precipitation studies.
Transfection and luciferase reporter assays. In all transfection-based studies 
(including knockdown experiments with 20 nM siRNA and 2 µg/ml shRNA) 
in HEK293 cells we used Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions. For luciferase reporter assays, HEK293 TLR3 
cells were seeded (1.5 × 105 cells/ml; 200 µl) in 96-well plates and transfected 
with constructs encoding IFN-β, IFN-α4 or PRDI-III–regulated firefly luci-
ferase (80 ng) or pFR firefly luciferase reporter construct (60 ng) with Gal4-
IRF3 (30 ng) or Gal4-IRF7 (25 ng), TK Renilla luciferase reporter construct 
(phRL-TK; 20 ng; Promega Biosciences) and Pellino3 expression constructs 
(1–20 ng). Total DNA was kept constant (200 ng/well) using the appropriate 
empty vector. Cells were treated as indicated and cell lysates assayed for firefly 
luciferase activity and normalized for transfection efficiency using TK Renilla 
luciferase activity.
For studies using transfection-mediated delivery of poly(I:C), BMDMs were 
seeded (5 × 105 cells/ml; 200 µl) in 96-well plates and grown for 24 h. Cells 
were then transfected using Lipofectamine 2000 with 5 µg/ml poly(I:C) and 
incubated for 24 h. Conditioned supernatant was assayed by ELISA.
Lentiviral production and transduction. PELI3-specific shRNA was used 
to suppress endogenous expression of Pellino3 in U373 cells as previously 
described49. Knockdown efficiency was assessed by RT-PCR.
Retroviral production and transduction. MEFs were seeded (3 × 105 cells/ml; 
3 ml) into 6-well plates (for quantitative PCR) or in 90 mm dishes (for immuno-
precipitation) and were transduced with a MSCV retroviral plasmid encoding 
mouse (m)Pellino3 or the mPellino3 RING mutant as described49.
Quantitative PCR. RNA was extracted from cells using Tri-Reagent 
(Sigma) and cDNA generated using AMV reverse transcriptase (Promega). 
Samples were assayed by quantitative real time PCR using the CFB-
322001G Opticon thermal cycler (Bio-Rad Laboratories) with Brilliant 
SYBR Green QPCR master mix (Stratagene) and the following primers: 
mIFN-α forward, GGCTTGACACTCCTGGTACAAATGAG; mIFN-α 
reverse, CAGCACATTGGCAGAGGAAGACAG; hIFN-α forward, GAA
ATACTTCCAAAGAATCACTCT; hIFN-α reverse, GATCTCATGATTT
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CTGCTCTGACA; mIFN-β forward, GGAGATGACGGAGAAGATGC; 
mIFN-β reverse, CCCAGTGCTGGAGAAATTGT; hIFN-β, forward, AACT 
GCAACCTTTCGAAGCC; hIFN-β reverse, TGTCGCCTACTACCTGTTG 
TGC; mTNF-α forward, CATCTTCTCAAAATTCGAGTGACAA; mTNF-α 
reverse, TGGGAGTAGACAAGGTACAACCC; hIL6 forward, AGCCACTCA 
CCTCTTCAGAACGAA; hIL6 reverse, CAGTGCCTCTTTGCTGCTTTCA 
CA; mPellino3 forward, ACATGCCAACGGAGTGAAGC; mPellino3 reverse, 
AGCGGCCAATCTGGAACAT; mRANTES forward, GGAGATGAGCTA 
GGATAGAGGG; mRANTES reverse, TGCCCATTTTCCCAGGACCG; 
hRANTES forward, TGCCTGTTTCTGCTTGCTCTTGTC; hRANTES 
reverse, TGTGGTAGAATCTGGGCCCTTCAA; mCXCL10 forward, GACGG 
TCCGCTGCAACTG; mCXCL10 reverse, GCTTCCCTATGGCCCTCATT; 
hCXCL10 forward, ATTATTCCTGCAAGCCAATTTTG; hCXCL10 reverse, 
TCACCCTTCTTTTTCATTGTAGCA; mHPRT forward, GCTTGCTGGTG
AAAAGGACCTCTCGAAG; mHPRT reverse, CCCTGAAGTACTCATTAT
AGTCAAGGGCAT; hHPRT forward, AGCTTGCTGGTGAAAAGGAC; and 
hHPRT reverse, TTATAGTCAAGGGCATATCC.
Confocal microscopy. MEFs were seeded (3 × 105 cells/ml) on poly- 
l-lysine–coated slides and treated with 25 µg/ml poly(I:C) for 90 min. Cells 
were washed three times in chilled PBS (500 µl), fixed with 4% (v/v) parafor-
maldehyde (500 µl) for 20 min, permeabilized with 0.2% Triton X-100 for 10 
min and blocked with 10% goat serum (Vector Laboratories) for 2 h. Cells 
were incubated overnight at 4 °C with anti-IRF7 antibody (1:200; F-1, Santa 
Cruz), washed and incubated with goat anti-mouse Alexa Fluor 488–labeled 
secondary antibody (1:500; A-11001, Invitrogen). Nuclei were stained with 
DAPI (1.5 µg/ml; Sigma) for 2 min. Cells were mounted and confocal images 
were captured using the ×63 objective lens (×630 total magnification) on the 
UV Zeiss 510 Meta System laser scanning microscope and analyzed using the 
LSM5 browser imaging software.
Isolation of nuclear fractions. BMDMs were seeded (5 × 105 cells/ml) and 
treated with 5 µg/ml poly(I:C) durations indicated for each experiment. Cells 
were resuspended for 10 min on ice in buffer A: 10 mM HEPES pH 7.9, 10 mM 
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1 mM Na3VO4 followed by additional 
washes in buffer A. The nuclear pellet was resuspended in three volumes of 
ice-cold buffer B: 20 mM HEPES pH 7.9, 10 mM KCl, 1 mM EDTA, 1 mM 
EGTA, 420 mM NaCl and 20% glycerol. Samples were centrifuged at 12,000g 
for 10 min, and the supernatants constituted nuclear fractions that were immu-
noblotted using anti-IRF7 (ab109255, Abcam), anti-IRF3 (sc-9082, Santa 
Cruz) and anti-nucleolin (sc-13057, Santa Cruz) antibodies.
Chromatin immunoprecipitation assay. Chromatin immunoprecipita-
tion (ChIP) assays were performed essentially as previously described48 
using anti-IRF7 antibody (ab109255, Abcam) or mouse IgG (12-371, 
Upstate Laboratories). Standard PCR was conducted with specific prim-
ers (5′-AAGACAAAATGACAGAGGA-3′ and reverse, 5′-ATGGTCCTT 
TCTGCCTCA-3′) designed to amplify the enhanceosome region of the 
Ifnb1 promoter.
Statistical analysis. Data are the means ± s.e.m. of triplicate determinations 
from three independent experiments. For comparison between two groups, 
Student’s two-tailed paired t-test was used. For comparison between two or more 
groups one-way ANOVA was applied. P < 0.05 was considered significant.
48. Curran, N.M. et al. The synthetic cannabinoid R(+)WIN 55,212–2 inhibits the 
interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-
independent manner. J. Biol. Chem. 280, 35797–35806 (2005).
49. Mellett, M., Atzei, P., Jackson, R., O′Neill, L.A. & Moynagh, P.N. Mal mediates TLR-
induced activation of CREB and expression of IL-10. J. Immunol. 186, 4925–4935 
(2011).
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